Promising Biotech Stocks To Watch Today – March 27th

AbbVie, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, Royalty Pharma, Moderna, and IQVIA are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of companies that focus on research and development in the biotechnology field, often working on innovative treatments and healthcare solutions derived from biological systems. These stocks tend to be highly volatile due to the risks associated with groundbreaking research, regulatory approvals, and the competitive nature of the industry, but they also offer significant growth potential if key milestones are met. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of AbbVie stock traded up $1.26 on Thursday, hitting $202.56. The stock had a trading volume of 1,313,680 shares, compared to its average volume of 5,261,400. The stock has a market cap of $357.59 billion, a price-to-earnings ratio of 84.34, a PEG ratio of 1.62 and a beta of 0.61. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. The stock’s 50-day simple moving average is $196.25 and its two-hundred day simple moving average is $188.87. AbbVie has a one year low of $153.58 and a one year high of $218.66.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of NYSE:TMO traded down $0.71 during midday trading on Thursday, hitting $512.97. 423,100 shares of the stock traded hands, compared to its average volume of 1,907,178. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $193.52 billion, a PE ratio of 31.03, a P/E/G ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific has a one year low of $493.30 and a one year high of $627.88. The business’s 50 day moving average is $543.80 and its two-hundred day moving average is $553.93.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

DHR traded down $0.38 during midday trading on Thursday, reaching $210.03. 894,685 shares of the company’s stock traded hands, compared to its average volume of 3,007,396. The stock has a market capitalization of $150.11 billion, a price-to-earnings ratio of 39.80, a P/E/G ratio of 2.66 and a beta of 0.82. Danaher has a 52 week low of $196.80 and a 52 week high of $281.70. The firm has a fifty day moving average of $215.86 and a two-hundred day moving average of $237.56. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Shares of Vertex Pharmaceuticals stock traded up $3.87 during midday trading on Thursday, reaching $504.15. 234,780 shares of the company’s stock traded hands, compared to its average volume of 1,442,947. The stock has a 50 day moving average of $473.33 and a 200-day moving average of $463.34. Vertex Pharmaceuticals has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a market cap of $129.46 billion, a PE ratio of -229.05, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69.

Royalty Pharma (RPRX)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Royalty Pharma stock traded down $0.09 during mid-day trading on Thursday, reaching $31.47. 3,136,025 shares of the company traded hands, compared to its average volume of 2,900,006. The firm’s 50 day moving average price is $32.42 and its 200 day moving average price is $28.80. Royalty Pharma has a 52-week low of $24.05 and a 52-week high of $34.20. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The firm has a market capitalization of $18.14 billion, a price-to-earnings ratio of 21.72, a P/E/G ratio of 2.31 and a beta of 0.47.

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Shares of MRNA stock traded up $0.17 during midday trading on Thursday, reaching $31.65. 2,317,779 shares of the stock were exchanged, compared to its average volume of 6,654,178. Moderna has a 1 year low of $29.25 and a 1 year high of $170.47. The firm has a market cap of $12.24 billion, a PE ratio of -3.41 and a beta of 1.86. The company’s 50 day moving average is $34.81 and its two-hundred day moving average is $45.02.

IQVIA (IQV)

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Shares of NYSE:IQV traded down $1.20 on Thursday, hitting $178.82. 408,509 shares of the company traded hands, compared to its average volume of 1,451,749. The company has a market cap of $31.53 billion, a PE ratio of 23.84, a PEG ratio of 1.99 and a beta of 1.50. The stock has a 50 day simple moving average of $193.92 and a 200-day simple moving average of $207.10. IQVIA has a 52 week low of $176.74 and a 52 week high of $253.84. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.